Search

Your search keyword '"Pellicanò, G"' showing total 272 results

Search Constraints

Start Over You searched for: Author "Pellicanò, G" Remove constraint Author: "Pellicanò, G"
272 results on '"Pellicanò, G"'

Search Results

2. Causes of discontinuation of long-acting cabotegravir and rilpivirine in clinical practice: results from the prospective multicentre SCOLTA cohort

3. TD-1 Efficacy, safety and metabolic changes at 6-months after switch to long-acting injectable CAB/RPV: results from an observational prospective multicenter study

4. Low level viremia at the beginning and in course of long-acting treatment with injectable cabotegravir and rilpivirine

5. Lipids, weight gain and body mass index in ARV experienced PLWH treated with doravirine-based treatments: a comparison between dual or triple regimens vs bictegravir based triple regimen

6. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

7. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study

8. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project

10. Proposal of model for personalized early adapted cancer screening in people living with HIV: experience of "Gaetano Martino" Hospital University of Messina.

11. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

12. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir

13. Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

14. Incident diabetes in course of antiretroviral therapy

15. Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens

16. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study

21. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

22. Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti?

23. Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study

24. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

26. New treatment strategies for HIV-positive cancer patients undergoing anticancer medical treatment: update of the literature.

28. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

30. Durability of rilpivirine- versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy

31. Impact of the COVID-19 pandemic on HPV vaccination coverage in the general population and in PLWHs.

32. Transmission mode associated with coronavirus disease 2019: a review

34. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

35. Splenic abscesses in childhood brucellosis: a case-based review.

38. Squillace N, Menzaghi B, Migliorino GM, De Socio GV, Passerini S, Martinelli C, Mameli MS, Maggi P, Falasca K, Cordier L, Celesia BM, Salomoni E, Di Biagio A, Pellicanò G, Bonfanti P. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide and cholesterol increase: impact on cardiovascular risk assessment. Journal of HIV and Ageing

39. Epstein Barr Virus related cancer in people living with HIV: a review of the literature

40. Safety of hospital discharge before return of bowel function after elective colorectal surgery

41. Factors associated with hospital admission for COVID-19 in HIV patients

43. The new era of vaccines: the 'nanovaccinology'

44. Factors Associated With Weight Gain in People Treated With Dolutegravir

45. Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV

46. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

49. Predictors of severe weight gain in patients treated with Dolutegravir

Catalog

Books, media, physical & digital resources